Probiotic Chewables in Allergic Rhinoconjunctivitis Patients

Allergic Rhinoconjunctivitis Clinical Trial

Official title:

Study of the Probiotic Potential of a Lacticaseibacillus Strain in the Upper Airways in Patients With Allergic Rhinoconjunctivitis After Administration in a Chewable

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04898686
• Other study ID #: B3002020000086
• Status: Completed
• Phase: N/A
• Start date: August 1, 2020
• Est. completion date: August 6, 2021

Study information

• Verified date: April 2022
• Source: University Hospital, Antwerp
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

With this double- blind, randomised, placebo-controlled study, the investigators want to investigate the influence of a chewable with the probiotic strain Lacticaseibacillus rhamnosus GG on the symptoms and immunological markers of allergic rhinoconjunctivitis (AR). In addition, the investigators aim to study the influence of this probiotic chewable on the microbiome of the upper respiratory tract after administration in adults with AR. The bacterial and cytokine profiles in the naso- and oropharynx will be monitored before, during and after the treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 64
• Est. completion date: August 6, 2021
• Est. primary completion date: August 6, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adults aged 18 at the time of registration;
• Seasonal allergic rhinoconjunctivitis (AR) in the context of grass pollen allergy diagnosed on the basis of anamnesis cfr. ARIA guidelines and positive skin prick test and / or immunocap assay;
• Positive skin prick test (SPT) for grass pollen and / or the presence of specific IgE for grass pollen, confirmed by a medical specialist, measured at the start of the study: Soluprick SQ Phleum pratense pollen 10 HEP - ALK and / or IgE specific immunocap assay Phleum pratense (timothy grass) (g6);
• Body Mass Index in the range of 19-32 kg / m2;
• Instructed during screening and agreed not to use other probiotic products outside of the study during the study period;
• Signed the consent form.

Exclusion Criteria:

• Antibiotic use at baseline and during the study;
• Pregnant women;
• Unstable / uncontrolled asthma (to be determined by investigator-physician);
• Sensitization to dust mites
• History of probiotic use in the past two weeks;
• Current diagnosis of cancer or immunosuppressive therapy within the past 6 months;
• Abnormalities of the oral mucosa;
• Acute and chronic infectious and inflammatory upper airway diseases (eg acute / chronic rhinosinusitis cfr. EPOS guidelines);
• Clinically significant bleeding disorder;
• Any other medical condition that, in the principal investigator's opinion, warrants exclusion from the trial;
• History of regular use (> 3 days out of 7) of tobacco products within the previous two weeks

Related Conditions & MeSH terms

• Allergic Rhinoconjunctivitis
• Conjunctivitis
• Conjunctivitis, Allergic

Intervention

Biological:
• Probiotic chewables
chewables containing Lacticaseibacillus rhamnosus GG
• Placebo chewables
chewables without probiotic strain. Ingredients: Xylitol, microcrystalline cellulose, stearic acid, natural orange flavor, silica, magnesium stearate, citric acid and malic acid.

Locations

Country	Name	City	State
Belgium	Antwerp University Hospital	Edegem

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Antwerp	DSM Nutritional Products, Inc.

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Transfer of L. rhamnosus GG (estimated CFU counts) to the oronasopharyngeal cavity after administration of the chewable	qPCR	at 8 weeks
Primary	Changes in the score of allergic rhinitis symptoms	Daily questionnaires will be used, in which a self-reported Total Nasal Symptom Score (TNSS) based on rhinorrhea, nasal congestion, nasal itching and sneezing with symptom severity ranging from 0 (no problem) to 12 (very severe problem) will be recorded.	over the study period (= 10 weeks)
Secondary	changes in microbiome of the oronasopharyngeal region after administration of the chewable	16S rRNA amplicon sequencing	baseline, 8 weeks
Secondary	Inlfuence on general nose- and mouth health	A clinical evaluation by an ENT specialist will be performed at the start and 8 weeks of the study to assess the general nose and mouth health of the participants. Questions on discomfort and symptoms of inflammation or infection in the nose and mouth will be included in the Sino-Nasal Outcome Test (SNOT-22)-based questionnaire implemented at the start, week 8 and week 10. Symptoms will be scored from 0 (no problem) to 5 (very severe problem)	baseline, 8 weeks, 10 weeks
Secondary	Changes in the absolute numbers of specific airway pathogens and viruses	qPCR	baseline, 8 weeks
Secondary	Changes in cytokine levels (e.g. IL-10, IL-4, IL-5, IL-13) in oro- and nasopharynx samples, and cytokine and antibody levels in blood samples	qPCR and/or ELISA	baseline, 8 weeks
Secondary	Frequency of medication use	Daily questionnaires will be used where the type and frequency of medication use should be recorded	over the study period (= 10 weeks)